These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 24363283)

  • 1. Intratumoral Mistletoe (Viscum album L) Therapy in Patients With Unresectable Pancreas Carcinoma: A Retrospective Analysis.
    Schad F; Atxner J; Buchwald D; Happe A; Popp S; Kröz M; Matthes H
    Integr Cancer Ther; 2014 Jul; 13(4):332-40. PubMed ID: 24363283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use and safety of intratumoral application of European mistletoe (Viscum album L) preparations in Oncology.
    Steele ML; Axtner J; Happe A; Kröz M; Matthes H; Schad F
    Integr Cancer Ther; 2015 Mar; 14(2):140-8. PubMed ID: 25552476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular mistletoe therapy: friend or foe in established anti-tumor protocols? A multicenter, controlled, retrospective pharmaco-epidemiological study in pancreas cancer.
    Matthes H; Friedel WE; Bock PR; Zänker KS
    Curr Mol Med; 2010 Jun; 10(4):430-9. PubMed ID: 20455850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Phase I clinical trial of EUS-guided intratumoral injection of the oncolytic virus, HF10 for unresectable locally advanced pancreatic cancer.
    Hirooka Y; Kasuya H; Ishikawa T; Kawashima H; Ohno E; Villalobos IB; Naoe Y; Ichinose T; Koyama N; Tanaka M; Kodera Y; Goto H
    BMC Cancer; 2018 May; 18(1):596. PubMed ID: 29801474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complementary Treatment with Mistletoe Extracts During Chemotherapy: Safety, Neutropenia, Fever, and Quality of Life Assessed in a Randomized Study.
    Pelzer F; Tröger W; Nat DR
    J Altern Complement Med; 2018; 24(9-10):954-961. PubMed ID: 30247950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Viscum album [L.] extract therapy in patients with locally advanced or metastatic pancreatic cancer: a randomised clinical trial on overall survival.
    Tröger W; Galun D; Reif M; Schumann A; Stanković N; Milićević M
    Eur J Cancer; 2013 Dec; 49(18):3788-97. PubMed ID: 23890767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health services research of integrative oncology in palliative care of patients with advanced pancreatic cancer.
    Axtner J; Steele M; Kröz M; Spahn G; Matthes H; Schad F
    BMC Cancer; 2016 Aug; 16():579. PubMed ID: 27485618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interaction of standardized mistletoe (Viscum album) extracts with chemotherapeutic drugs regarding cytostatic and cytotoxic effects in vitro.
    Weissenstein U; Kunz M; Urech K; Baumgartner S
    BMC Complement Altern Med; 2014 Jan; 14():6. PubMed ID: 24397864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Chemotherapy of pancreatic carcinoma].
    Lutz MP
    Praxis (Bern 1994); 2005 Jun; 94(22):933-5. PubMed ID: 15986638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of high-dose intravenous mistletoe therapy in pediatric cancer patients: A case series.
    Zuzak TJ; Wasmuth A; Bernitzki S; Schwermer M; Längler A
    Complement Ther Med; 2018 Oct; 40():198-202. PubMed ID: 30219449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frontline treatment with gemcitabine, oxaliplatin and erlotinib for the treatment of advanced or metastatic pancreatic cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG).
    Katopodis O; Souglakos J; Stathopoulos E; Christopoulou A; Kontopodis E; Kotsakis A; Kalbakis K; Kentepozidis N; Polyzos A; Hatzidaki D; Georgoulias V
    Cancer Chemother Pharmacol; 2014 Aug; 74(2):333-40. PubMed ID: 24930058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sustained partial remission of metastatic pancreatic cancer following systemic chemotherapy with gemcitabine and oxaliplatin plus adjunctive treatment with mistletoe extract.
    Ritter PR; Tischoff I; Uhl W; Schmidt WE; Meier JJ
    Onkologie; 2010; 33(11):617-9. PubMed ID: 20975309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Efficacy of gemcitabine-based chemotherapy on advanced pancreatic cancer].
    Gong JF; Zhang XD; Li J; Di LJ; Jin ML; Shen L
    Ai Zheng; 2007 Aug; 26(8):890-4. PubMed ID: 17697554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
    Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V;
    Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug Interactions Causing Warfarin Overdose in a Patient with Pancreatic Cancer: A Case Report.
    Moussouni M; Graff V; Couturier F; Herrscher H
    Chemotherapy; 2023; 68(2):111-114. PubMed ID: 36446317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of Capecitabine Plus Oxaliplatin Combination Chemotherapy for Advanced Pancreatic Cancer after Failure of First-Line Gemcitabine-Based Therapy.
    Chung KH; Ryu JK; Son JH; Lee JW; Jang DK; Lee SH; Kim YT
    Gut Liver; 2017 Mar; 11(2):298-305. PubMed ID: 27965478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Efficacy and safety of long-term complementary treatment with standardized European mistletoe extract (Viscum album L.) in addition to the conventional adjuvant oncologic therapy in patients with primary non-metastasized mammary carcinoma. Results of a multi-center, comparative, epidemiological cohort study in Germany and Switzerland].
    Bock PR; Friedel WE; Hanisch J; Karasmann M; Schneider B
    Arzneimittelforschung; 2004; 54(8):456-66. PubMed ID: 15460213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group.
    Pelzer U; Schwaner I; Stieler J; Adler M; Seraphin J; Dörken B; Riess H; Oettle H
    Eur J Cancer; 2011 Jul; 47(11):1676-81. PubMed ID: 21565490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemotherapy for advanced pancreatic adenocarcinoma in elderly patients (≥70 years of age): a retrospective cohort study at the National Center for Tumor Diseases Heidelberg.
    Berger AK; Abel U; Komander C; Harig S; Jäger D; Springfeld C
    Pancreatology; 2014; 14(3):211-5. PubMed ID: 24854617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metastatic Pancreatic Adenocarcinoma Treatment Patterns, Health Care Resource Use, and Outcomes in France and the United Kingdom Between 2009 and 2012: A Retrospective Study.
    Smyth EN; Bapat B; Ball DE; André T; Kaye JA
    Clin Ther; 2015 Jun; 37(6):1301-16. PubMed ID: 25907619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.